Patients Sponsored 12 Questions with Kim Innes Kim Innes is General Manager of Teva UK. She has more than 30 years’ experience across the pharmaceutical industry.
News Sandoz will pay another $480m to settle US antitrust suits Sandoz has reached a settlement in the US that, if approved, could lay to rest years of litigation over price-fixing of generic medicines.
News Trump sets course for 100%, then 200%, tariffs on generics Trump has said he intends to impose tariffs of 100% on generic drugs imported into the US from 2028, rising to 200% after a year, in a reshoring push.
News FDA approves first generic of Roche's flu drug Xofluza The first generic of Roche's drug for influenza, Xofluza, has been approved by the FDA and should be available in time for this year's flu season.
Patients Biosimilars & patient access independent of geographies or s... Rebecca Guntern, Sandoz' CCO, discusses the ‘golden decade’ for generics and biosimilars as so many blockbuster drugs come off patent.
News SCOTUS backs generic firm Hikma in skinny label dispute SCOTUS has delivered its ruling in a closely watched 'skinny label' lawsuit between Amarin and Hikma, which could have far-reaching implications.
News TransThera's resistant biliary cancer drug cleared in China TransThera's Yochanra has been cleared in China as the world's first drug that can overcome resistance to FGFR inhibitors in cholangiocarcinoma.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
